Porfimer sodium photodynamic therapy for management of Barrett's esophagus with high-grade dysplasia

Lasers in Surgery and Medicine

Volumn 38, Issue 5, 2006, Pages 390-395

  Panjehpour, Masoud ^a   Overholt, Bergein F ^a  

^a THOMPSON CANCER SURVIVAL CENTER   (United States)

Author keywords

Adenocarcinoma of esophagus; Argon dye laser; Diode laser; KTP dye laser; PDT; Porfimer sodium; Thermal ablation

Indexed keywords

ANTICOAGULANT AGENT; METHYLPREDNISOLONE ACETATE; PHOTOFRIN; PHOTOSENSITIZING AGENT; STEROID;

ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIODE LASER; DYE LASER; DYSPHAGIA; DYSPLASIA; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC MUCOSAL RESECTION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS DILATATION; ESOPHAGUS PERFORATION; ESOPHAGUS STRICTURE; EYE PROTECTION; FEVER; FOLLOW UP; HEART ATRIUM FIBRILLATION; HICCUP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEODYMIUM LASER; PATIENT EDUCATION; PATIENT SELECTION; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY DISORDER; PHOTOTOXICITY; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN PROTECTION; SUN EXPOSURE; THORAX PAIN; THROMBOEMBOLISM; VOMITING;

ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; CATHETER ABLATION; DIHEMATOPORPHYRIN ETHER; ESOPHAGEAL NEOPLASMS; ESOPHAGEAL STENOSIS; HUMANS; MUCOUS MEMBRANE; OMEPRAZOLE; PATIENT SELECTION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PRECANCEROUS CONDITIONS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 33745727971     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.20367     Document Type: Article

References (23)

1. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lines (Barrett's) esophagus. N Engl J Med 1985;313:857-859.
2. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991;32:1441-1446.
3. Williamson WA, Ellis FH, Jr., Gibb SP, et al. Barrett's esophagus: Prevalence and incidence of adenocarcinoma. Arch Intern Med 1991;151:2212-2216.
4. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-1137.
5. Bonavina L. Early oesophageal cancer: Results of a European multicenter survey. Group European pour l'Etude des Maladies de l'Oesophage. Br J Surg 1995;82:98-101.
6. Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 1996;224:66-71.
7. Holscher AH, Bollschweiler E, Schneider PM, Siewert JR. Early adenocarcinoma in Barrett's esophagus. Br J Surg 1997;84:1470-1473.
8. Nigro JJ, Hagen JA, DeMeester TR, et al. Occult esophageal adenocarcinoma: Extent of disease and implications for effective therapy. Ann Surg 1999;230:433-438.
9. Rice TW, Falk GW, Achkar E, Petras RE. Surgical management of high grade dysplasia in Barrett's esophagus. Am J Gastroenterol 1993;88:1832-1836.
10. Thomas P, Doddoli C, Neville P, et al. Esophageal cancer resection in the elderly. Eur J Cardiothorac Surg 1996;10:941-946.
11. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: Follow-up in 100 patients. Gastrointest Endosc 1999;49:1-7.
12. Panjehpour M, Overholt BF, Haydek JM, Lee SG. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation. Am J Gastroenterol 2000;95:2177-2184.
13. Wang KK. Current status of photodynamic therapy of Barrett's esophagus. Gastrointest Endosc 1999;49(3) part 2:S20-S23.
14. Wolfsen HC, Hemminger LL, Wallace MB, Devault KR. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer. Aliment Pharmacol Ther 2004;20:1125-1131.
15. Overholt BF, Lightdale CJ, Wang KK, Canto MI, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: International, partially blinded, randomized phase III trial. Gastrointest Endosc 2005;62:488-498.
16. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: Long-term results. Gastrointest Endosc 2003;58:183-188.
17. Wolfsen HC. Present status of photodynamic therapy for high grade dysplasia in Barrett's esophagus. J Clin Gastroenterol 2005;39:189-202.
18. Wang KK. Combined endoscopic mucosal resection and photodynamic therapy for high grade dysplasia and early cancer in Barrett's esophagus. Tech Gastrointest Endosc 2005;7:69-72.
19. Panjehpour M, Overholt BF, Haydek JM. Light sources and delivery devices for photodynamic therapy in the gastrointestinal tract. Gastrointest Endosc Clin N Am 2000;10(3): 513-532.
20. Brandth LJ, Blansky RL, Kauvar DR. Repeat laser therapy of recurrent Barrett's epithelium: Success with anacidity. Gastrointest Endosc 1995;41:267.
21. Malhi-Chowla N, Wolfsen HC, DeVault KR. Esophageal dysmotility in patients undergoing photodynamic therapy. Mayo Clin Proc 2001;76:987-989.
22. Overholt BF, Panjehpour M, Ayres M. Photodynamic therapy for Barrett's esophagus: Cardiac effects. Lasers Surg Med 1997;21:317-320.
23. Phan M, Dyke S, Whittaker MA, Simmerman A, Abrams S, Panjehpour M, Overholt BF. An educational tool for photodynamic therapy of Barrett's esophagus with high-grade dysplasia. Gastroenterol Nurs 2005;28(5):413-419.